-
11.发明申请公开(公告)号：US20110137283A1
公开(公告)日：2011-06-09
申请号：US13027447
申请日：2011-02-15
CPC分类号： A61K38/38 , C07K14/765
摘要： A process for purifying and collecting albumin from plasma and plasma fractions involves diafiltration of an albumin-containing plasma fraction; stabilizing the resulting albumin fraction with sodium chloride and an amino acid in the absence of any added fatty acid; pasteurizing the stabilized albumin fraction; and diafiltering the pasteurized fraction to remove, along other things, stabilizers. In one embodiment, the amino acid stabilizing agent is acetyl tryptophan. The resulting albumin has at least about 80% albumin binding capacity relative to natural plasma albumin, and is storage stable for about 30 months at 30° C.
摘要翻译： 从血浆和血浆级分纯化和收集白蛋白的方法包括对含白蛋白的血浆级分进行渗滤; 在没有任何添加的脂肪酸的情况下用氯化钠和氨基酸稳定所得的白蛋白部分; 将稳定的白蛋白部分巴氏消毒; 并且将巴氏消毒馏分直接过滤以除去稳定剂。 在一个实施方案中，氨基酸稳定剂是乙酰色氨酸。 所得白蛋白相对于天然血浆白蛋白具有至少约80％的白蛋白结合能力，并且在30℃下储存稳定约30个月。
-
12.发明授权Composition of biocompatible microparticles of alginic acid for the controlled release of active ingredients by intravenous administration 有权用于通过静脉内施用控制释放活性成分的藻酸的生物相容性微粒的组成公开(公告)号：US07931916B2
公开(公告)日：2011-04-26
申请号：US12634203
申请日：2009-12-09
申请人： Salvador Grancha Gamon , Anna Nardi Ricart , Josep Mariá Suñe Negre , Josep Ramón Tico Grau , Montserrat Miñarro Carmona
发明人： Salvador Grancha Gamon , Anna Nardi Ricart , Josep Mariá Suñe Negre , Josep Ramón Tico Grau , Montserrat Miñarro Carmona
IPC分类号： A61K9/14
CPC分类号： A61K38/37 , A61K9/0019 , A61K9/5036 , A61K9/5089 , A61K38/4846
摘要： Composition of biocompatible microparticles of alginic acid for the controlled release of active ingredients by intravenous administration. The invention relates to a biocompatible composition which comprises microparticles of alginic acid or its salts and an active ingredient. More particularly, the invention relates to microparticles for the encapsulation of an active ingredient to be administered intravenously to a patient who needs it. These microparticles are of a combination of size sufficient to increase the half-life or survival of the active ingredient in blood, with a low uptake in the liver and a fast cell clearance when administered intravenously.
摘要翻译： 用于通过静脉内施用控制释放活性成分的藻酸的生物相容性微粒的组成。 本发明涉及包含藻酸或其盐的微粒和活性成分的生物相容性组合物。 更具体地，本发明涉及用于将待静脉内施用的活性成分包封的微粒用于需要它的患者。 这些微粒具有足以增加血液中活性成分的半衰期或存活的尺寸的组合，在肝脏中摄取量低，并且静脉内施用时具有快速的细胞清除率。
-
公开(公告)号：US20100312274A1
公开(公告)日：2010-12-09
申请号：US12759954
申请日：2010-04-14
IPC分类号： A61B17/03
CPC分类号： A61B17/00491 , A61B2017/00495 , A61M5/19 , A61M5/315
摘要： A device for the application of two components of fibrin adhesive at a treatment site comprising a support for syringes comprising two parallel cylindrical housings to receive corresponding syringes and a plunger connecting member, characterised in that the said syringe support comprises a passage for insertion of the said plunger connecting member, the said passage being located in the space defined between the cylindrical housings of the said syringe support, the said plunger connector having a zone with a suitable geometry to slide within the said passage and in that the transverse cross-section of the said passage of the syringe support has a maximum opening at the ends and a minimum opening in the central part.
摘要翻译： 一种用于在治疗部位应用纤维蛋白粘合剂的两个组分的装置，其包括用于注射器的支撑件，所述支架包括两个平行的圆柱形壳体以接收相应的注射器和柱塞连接构件，其特征在于，所述注射器支架包括用于插入所述 柱塞连接构件，所述通道位于限定在所述注射器支撑件的圆柱形壳体之间的空间中，所述柱塞连接器具有适当几何形状的区域，以在所述通道内滑动，并且所述柱塞连接构件的横截面 注射器支架的所述通道在端部具有最大开口并且在中心部分具有最小开口。
-
公开(公告)号：US20100221765A1
公开(公告)日：2010-09-02
申请号：US12434813
申请日：2009-05-04
CPC分类号： G01N21/253 , G01N21/278 , G01N21/82 , G01N2021/5969 , G01N2021/8829
摘要： The invention comprises taking colour pictures of back-lighted analysis microtubes and using the colour information in the images to identify areas of the image which are relevant for interpreting the result of other possible artefacts, as well as detecting abnormal samples and/or reactions characterised by changes in the colour properties of the reaction.
摘要翻译： 本发明包括拍摄背光分析微管的彩色图像，并使用图像中的颜色信息来识别图像的与解释其它可能的人工制品的结果相关的区域，以及检测以下特征的异常样品和/或反应： 反应颜色特性的变化。
-
公开(公告)号：US20090293644A1
公开(公告)日：2009-12-03
申请号：US12469355
申请日：2009-05-20
申请人： Marc PELLICER SANCHO
发明人： Marc PELLICER SANCHO
IPC分类号： G01N1/10
CPC分类号： G01N35/025 , G01N35/026 , G01N2035/00148 , G01N2035/0425 , Y10T436/2575
摘要： The apparatus comprises a single transportable structure provided with several separate compartments located in a vertical stack within a cabinet, with means for the vertical transport of gel cards, means for the transport of units for moving the cards and pipetting probes, being displaceable to the entire transverse cross-section of the compartments in at least two of the vertical compartments or floors through moving along coordinate axes X, Y, Z at right-angles, and control means so that automatic functioning can take place simultaneously with manual actions to load and unload the necessary materials (samples, reagents, cards, wash solutions and waste solutions) in a random manner.
摘要翻译： 该装置包括单个可运输结构，其设置有位于机柜内的垂直堆叠中的几个单独的隔间，具有用于垂直运输凝胶卡的装置，用于运输用于移动卡和移液探针的单元的装置，可移位到整个 通过沿着坐标轴X，Y，Z以直角移动，并且控制装置在至少两个垂直隔间或地板中的隔室的横截面，使得自动功能可以与手动操作同时进行加载和卸载 必要的材料（样品，试剂，卡，洗液和废液）。
-
16.发明申请PROCESS FOR OBTAINING A CONCENTRATE OF VON WILLEBRAND FACTOR OR A COMPLEX OF FACTOR VIII/VON WILLEBRAND FACTOR AND USE OF THE SAME 有权获得VON WILLEBRAND因子浓度或因子VIII / VON WILLEBRAND因子复合物的方法及其使用公开(公告)号：US20090176709A1
公开(公告)日：2009-07-09
申请号：US12349604
申请日：2009-01-07
CPC分类号： C07K14/755 , A61K38/00
摘要： The process is characterised by the preparation of a solution of Von Willebrand Factor or a complex of Factor VIII/Von Willebrand Factor which contains VWF and a concentration of up to 12 IU VWF:RCo/ml and a Von Willebrand Factor/Factor VIII ratio of 0.4 or more; and then proceeding with nanofiltration of the solution prepared in a) through a filter having a pore size of less than 35 nanometres.
摘要翻译： 该方法的特征在于制备Von Willebrand因子或因子VIII / Von Willebrand因子的复合物，其含有VWF，浓度高达12IU VWF：RCo / ml和Von Willebrand因子/因子VIII比例 0.4以上; 然后通过孔径小于35纳米的过滤器对a）中制备的溶液进行纳滤。
-
17.发明授权Therapeutic human albumin solutions with low prekallikrein activator (PKA) activity and process for obtaining them 有权具有低激素释放激酶（PKA）活性的治疗性人白蛋白溶液及其获得的方法公开(公告)号：US07332577B2
公开(公告)日：2008-02-19
申请号：US11185613
申请日：2005-07-19
CPC分类号： A61K51/081
摘要： The invention discloses a purified albumin solution of human origin with low prekallicrein activator (PKA) activity and stability over time characterised in that it has an antithrombin content equal to or greater than 0.03 mg/g of albumin, and a process for production thereof by the partial extraction of the antithrombin during fractionation of the human plasma.
摘要翻译： 本发明公开了一种具有低前金属蛋白酶活化剂（PKA）活性的人源纯化白蛋白溶液和随时间的稳定性，其特征在于其抗凝血酶含量等于或大于0.03mg / g的白蛋白，及其制备方法 在人血浆分馏过程中部分提取抗凝血酶。
-
18.发明授权Process and apparatus for evaluating the degree of vacuum in closed bodies with transparent walls 有权用于评估具有透明壁的封闭体中的真空度的方法和装置公开(公告)号：US07323881B2
公开(公告)日：2008-01-29
申请号：US11556772
申请日：2006-11-06
申请人： Diego Lopez Alvarez
发明人： Diego Lopez Alvarez
CPC分类号： G01M3/40
摘要： The invention is based on feeding the closed bodies to be evaluated to a station for the application of high voltage for the formation of the arc across the inner space of the body and capturing the arc formed by means of a CCD camera which will compare, adjustably, the luminous intensity of the arc created within the body subjected to checking with a threshold value determining whether the luminous intensity is above or below the threshold, which will be the rejection threshold, rejecting the bodies which do not comply with the predetermined threshold value, separating them from the whole of the accepted bodies.
摘要翻译： 本发明基于将要评估的封闭体馈送到站，以施加用于在身体的内部空间形成电弧的高电压，并捕获通过CCD照相机形成的电弧，其可以可调节地比较 在经过检查的身体中产生的电弧的发光强度，该阈值确定发光强度是否高于或低于阈值，其将是拒绝阈值，拒绝不符合预定阈值的体， 将它们与整个被接受的身体分开。
-
19.发明申请THERAPEUTIC HUMAN ALBUMIN SOLUTIONS WITH LOW PREKALLICREIN ACTIVATOR (PKA) ACTIVITY AND PROCESS FOR OBTAINING THEM 有权具有低预激活素（PKA）活性的治疗人类ALBUMIN解决方案及其获取过程公开(公告)号：US20070161781A1
公开(公告)日：2007-07-12
申请号：US11689028
申请日：2007-03-21
IPC分类号： C07K14/765
CPC分类号： A61K51/081
摘要： The invention discloses a purified albumin solution of human origin with low prekallicrein activator (PKA) activity and stability over time characterised in that it has an antithrombin content equal to or greater than 0.03 mg/g of albumin, and a process for production thereof by the partial extraction of the antithrombin during fractionation of the human plasma.
摘要翻译： 本发明公开了一种具有低前金属蛋白酶活化剂（PKA）活性的人源纯化白蛋白溶液和随时间的稳定性，其特征在于其抗凝血酶含量等于或大于0.03mg / g的白蛋白，及其制备方法 在人血浆分馏过程中部分提取抗凝血酶。
-
公开(公告)号：US20060104862A1
公开(公告)日：2006-05-18
申请号：US11270346
申请日：2005-11-08
申请人： Josep Pages Pinyol
发明人： Josep Pages Pinyol
IPC分类号： G01N35/00
CPC分类号： G01N35/025 , G01N2035/0427 , G01N2035/0444 , G01N2035/0465 , Y10T436/11
摘要： The apparatus comprises an assembly of modules functionally interrelated with one another, and controlled by means of a central control unit in an embodiment of circular type in concentric rings of a reagent module and a rotatory carousel carrying the incubation reaction containers, with adjacent and external arrangement of a module for feeding the disposable reaction containers by means of detachable racks and a scanning device likewise concentric with the carousel, combining with a unit for feeding by pushing the reaction containers from the racks towards the grooves of the incubation carousel, and of two displacement arm devices.
-
-
-
-
-
-
-
-
-
搜索结果
92 条记录 (耗时 0.021 秒)
